Citation: Chavda, V .P .; Ajabiya, J.;
Teli, D.; Bojarska, J.; Apostolopoulos,
V . Tirzepatide, a New Era of
Dual-Targeted Treatment for Diabetes
and Obesity: A Mini-Review.
Molecules 2022 ,27, 4315. https://
doi.org/10.3390/molecules27134315
Academic Editor: Lars
Porskjær Christensen
Received: 7 June 2022
Accepted: 4 July 2022
Published: 5 July 2022
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional afﬁl-
iations.
Copyright: © 2022 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
molecules
Review
Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes
and Obesity: A Mini-Review
Vivek P . Chavda1,*
, Jinal Ajabiya2, Divya Teli3, Joanna Bojarska4,*,†
and Vasso Apostolopoulos5,6,*,†
1Department of Pharmaceutics and Pharmaceutical Technology, LM College of Pharmacy, Ahmedabad 380009,
India
2Department of Pharmaceutics Analysis and Quality Assurance, LM College of Pharmacy, Ahmedabad 380009,
India; 98jinal@gmail.com
3Department of Pharmaceutical Chemistry, LM College of Pharmacy, Ahmedabad 380009, India;
divya.teli@lmcp.ac.in
4Institute of General and Ecological Chemistry, Faculty of Chemistry, Lodz University of Technology,
116 ˙Zeromskiego Street, 90-924 Lodz, Poland
5Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia
6Australian Institute for Musculoskeletal Science (AIMSS), Immunology Program, Melbourne, VIC 3030,
Australia
*Correspondence: vivek.chavda@lmcp.ac.in (V .P .C.); joanna.bojarska@p.lodz.pl (J.B.);
vasso.apostolopoulos@vu.edu.au (V .A.)
† These authors contributed equally to this work.
Abstract: The prevalence of obesity and diabetes is an increasing global problem, especially in devel-
oped countries, and is referred to as the twin epidemics. As such, advanced treatment approaches
are needed. Tirzepatide, known as a ‘twincretin’, is a ‘ﬁrst-in-class’ and the only dual glucagon-like
peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP) receptor agonist, that can
signiﬁcantly reduce glycemic levels and improve insulin sensitivity, as well as reducing body weight
by more than 20% and improving lipid metabolism. This novel anti-diabetic drug is a synthetic pep-
tide analog of the human GIP hormone with a C 20fatty-diacid portion attached which, via acylation
technology, can bind to albumin in order to provide a dose of the drug, by means of subcutaneous
injection, once a week, which is appropriate to its a half-life of about ﬁve days. Tirzepatide, developed
by Eli Lilly, was approved, under the brand name Mounjaro, by the United States Food and Drug
Administration in May 2022. This started the ‘twincretin’ era of enormously important and appealing
dual therapeutic options for diabetes and obesity, as well as advanced management of closely related
cardiometabolic settings, which constitute the leading cause of morbidity, disability, and mortality
worldwide. Herein, we present the key characteristics of tirzepatide in terms of synthesis, structure,
and activity, bearing in mind its advantages and shortcomings. Furthermore, we brieﬂy trace the
evolution of this kind of medical agent and discuss the development of clinical studies.
Keywords: tirzepatide; twincretin; short peptide; incretins; diabetes; obesity
1. Introduction
Diabetes and obesity are chronic diseases leading to substantial morbidity and high
mortality worldwide, especially in developed countries. They are considered the twin
epidemics of the 21st century. Neither disorder is a simple problem; rather, both are complex
health issues combining genetic, epigenetic, and lifestyle factors, including socioeconomic
and environmental impacts [1–3].
Obesity is deﬁned by the World Health Organization (WHO) as an “abnormal or
excessive fat accumulation that may impair health” [ 4,5]. It is deﬁned by body mass
index (BMI), weight in kilograms divided by the square of height in meters, in adults over
30 kg /m2[6]. It should be highlighted that obesity is related to an increased risk of other
serious conditions and diseases such as diabetes, hypertension, cardiovascular disease,
Molecules 2022 ,27, 4315. https://doi.org/10.3390/molecules27134315 https://www.mdpi.com/journal/molecules
Molecules 2022 ,27, 4315 2 of 10
cancer, asthma, hypercholesterolemia, and so on [ 7]. To date, the ﬁght against obesity has
been one of the greatest challenges. Treatment has been based only on a well-balanced diet
and regular physical activity, so far.
Type 2 diabetes (T2D) is an incurable condition that inﬂuences glucose regulation in
the body. Cases are increasing daily at a menacing rate. The rise in the number of T2D cases
over a period of 34 years (1980–2014) was four-fold [ 8], with a 5% increase in premature
mortality from T2D from 2000 to 2016. Due to 1.5 million estimated deaths being directly
caused by T2D, it was termed the ninth-biggest mode of mortality in 2019 [ 9]. A whopping
537 million adults across the globe were suffering from T2D in the year 2021, and this
number is estimated to rise to 783 million by the year 2045 (with a surge of 12.2%) [ 10].
These statistics reveal that currently, 1 in 10 adults are suffering from T2D, and this number
is increasing at pandemic rates.
Beta cells that produce insulin, present in the pancreas, play a signiﬁcant role in
the origination and development of T2D by controlling the endocrine system for glucose
metabolism and glycemia. In T2D, these cells become inoperative in order to compensate
for insulin resistance, resulting in an insulin-deﬁcient condition called hyperglycemia.
Hyperglycemia can result in glucose toxicity that further deteriorates the function of beta
cells of the pancreas, giving rise to a deﬁciency of insulin in the body [11].
Treatment of T2D includes lifestyle changes such as diet, exercise, and nutraceuticals,
as well as administration of medications such as metformin. Various synthetic moieties
and herbal preparations have been developed to support the functioning of beta cells and
suppress harmful inﬂammatory responses [ 12]. The majority of these agents have unwanted
effects pertaining to the route of administration and various other factors. The common
side effects observed with the sulfonyl urea class of drugs include syncope, dizziness,
nervousness, anxiety, depression, and diarrhea. The adverse effect most associated with
metformin is gastrointestinal upset, and with repaglinide this is hypoglycemia [ 13,14]. In
such cases, only a small amount of medication reaches the cells. The therapeutic effect of
such kinds of drugs can be rapidly improved by targeting their delivery to the pancreatic
islets or by lowering the dose consumed, as well as by decreasing the side effects of
systematically administered agents [15].
Conventionally, two sorts of therapeutic agents have been used for the treatment
of T2D: insulin or its analogs, such as insulin lispro, insulin aspart, and oral agents like
glipizide, glimepride, metformin, acarbose, pioglitazone, saxagliptin [ 16]. In addition
to these agents, a short-acting insulin that can be inhaled just before nutrient intake—
Exubera®—was approved by the United States Food and Drug Administration (US FDA)
in January 2006 for therapeutic use [17].
Furthermore, products generated in the human body that stimulate beta cells to release
insulin, termed as ‘Incretins’, also known as ‘Incretin hormones’, were discovered in the
early 1970s. These products are secreted in the intestine, affecting the functioning of beta
cells (Figure 1). The most commonly known incretins include glucagon-like peptide-1
(GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) [18,19].
The adverse drug reaction proﬁle of tirzepatide is comparable to GLP-1 agonists, as it
is a dual GIP/GLP-1 agonist. The most common side effects associated with tirzepatide are
related to gastrointestinal tract like nausea, vomiting and diarrhea [ 20,21]. The incidence of
hypoglycemia is low, based on phase 2 trials [20].
The focus of this mini-review is to present a brief overview of the synthetic short pep-
tide tirzepatide as the ﬁrst dual GLP-1 and GIP receptor agonist as a promising therapeutic
agent for the treatment of either diabetes or obesity and to highlight its superiority to other
similar agents. Notably, modiﬁed short peptides have improved bio-functions compared
with those in the original analogs, and are of great promise in modern biomedicine thanks
to recent advances in science and biotechnology [ 22]. The most up-to-date pharmacologic
characterization of tirzepatide and its clinical evolution are discussed.
Molecules 2022 ,27, 4315 3 of 10
Molecules  2022, 27, x FOR PEER REVIEW   3 of 10 
 
  
Figure 1. Role of GLP‐1 in glucose metabolism.  
The focus of this mini‐review is to present a brief overview  of the synthetic  short 
peptide tirzepatide  as the first dual GLP‐1 and GIP receptor agonist as a promising  ther‐
apeutic agent for the treatment  of either diabetes or obesity and to highlight  its superiority  
to other similar agents. Notably,  modified  short peptides  have improved  bio‐functions  
compared  with those in the original analogs, and are of great promise in modern biomed‐
icine thanks to recent advances  in science and biotechnology  [22]. The most up‐to‐date 
pharmacologic  characterization  of tirzepatide  and its clinical evolution  are discussed.  
2. Methodology  
For the preparation  of this review, we carried out a literature  search using SciFinder®, 
PubMed,  and Scopus. The key words ‘tirzepatide  and Diabetes’,  ‘tirzepatide  and Obesity’,  
‘novel antidiabetics’  were used to search the related articles. In total, 90 articles were 
found containing  the two concepts  ‘tirzepatide’  and ‘Diabetes/Obesity’  closely associated  
with one another. From these, we included  those articles that employed  synthetic  meth‐
ods, in vivo study, or discussion  of tirzepatide  clinical trials. No conference  abstracts  or 
book chapters were included,  and only papers written in English language  were included.  
3. Insulinotropic  Peptides  
The effect caused by these insulinotropic  peptides  is called the ‘incretin effect’. This 
effect is characterized  by elevation  of glucose secretory  response  by oral glucose admin‐
istration in comparison  to intravenous  administration  even though they have similar 
plasma concentrations.  The name is given because it is believed to occur due to nutrients  
triggering  the release of incretin hormones  and also acting upon pancreatic  beta cells in 
an insulinotropic  manner (Figure 1) [23]. 
GLP‐1 and GIP are peptide hormones  that are secreted with the benefit of utilizing 
cells from intestines  called enteroendocrine  cells in reaction to the consumption  of nutri‐
ents, and they have an important  function in postprandial  metabolism.  With the identifi‐
cation of glucose equilibrium,  their most favorable  condition,  the incretin effect, begins to 
improve  the glucose‐stimulated  release of insulin from the pancreas.  GIP is considered  to 
be the essential  incretin hormone  accounting  for this effect, although  when administered  
together,  they exhibit a synergetic  effect [24]. 
The dipeptidylpeptidase ‐4 (DPP‐4) inhibitors  act by obstructing  the quick DPP‐4‐me‐
diated degradation  of endogenous  GLP‐1 and GIP, enhancing  their effectiveness.  
Figure 1. Role of GLP-1 in glucose metabolism.
2. Methodology
For the preparation of this review, we carried out a literature search using SciFinder®,
PubMed, and Scopus. The key words ‘tirzepatide and Diabetes’, ‘tirzepatide and Obesity’,
‘novel antidiabetics’ were used to search the related articles. In total, 90 articles were found
containing the two concepts ‘tirzepatide’ and ‘Diabetes/Obesity’ closely associated with
one another. From these, we included those articles that employed synthetic methods,
in vivo study, or discussion of tirzepatide clinical trials. No conference abstracts or book
chapters were included, and only papers written in English language were included.
3. Insulinotropic Peptides
The effect caused by these insulinotropic peptides is called the ‘incretin effect’. This
effect is characterized by elevation of glucose secretory response by oral glucose adminis-
tration in comparison to intravenous administration even though they have similar plasma
concentrations. The name is given because it is believed to occur due to nutrients trig-
gering the release of incretin hormones and also acting upon pancreatic beta cells in an
insulinotropic manner (Figure 1) [23].
GLP-1 and GIP are peptide hormones that are secreted with the beneﬁt of utilizing
cells from intestines called enteroendocrine cells in reaction to the consumption of nutrients,
and they have an important function in postprandial metabolism. With the identiﬁcation of
glucose equilibrium, their most favorable condition, the incretin effect, begins to improve
the glucose-stimulated release of insulin from the pancreas. GIP is considered to be the
essential incretin hormone accounting for this effect, although when administered together,
they exhibit a synergetic effect [24].
The dipeptidylpeptidase-4 (DPP-4) inhibitors act by obstructing the quick DPP-4-
mediated degradation of endogenous GLP-1 and GIP , enhancing their effectiveness. Mean-
while, the GLP-1 receptor agonists (RA), which have the advantage of an alteration in
structure, create resistance against the degradation of DPP-4 by intensifying the onset of
the GLP-1 receptor [ 25]. GLP-1 RAs also assist in the reduction of glucagon secretion of the
pancreas through alpha cells, reducing gastric emptying time and reducing appetite and
intake of nutrients, thus inducing weight loss in a manner different from glucose-dependent
stimulation. In contrast to externally administered GLP-1, which partly restores incretin
action in T2D patients, GIP infusion does not bring out a signiﬁcant insulin secretory
response, even at pharmacological concentrations [ 24]. For treatment of T2D, GIP-selective
RAs have not been widely considered, largely based on these ﬁndings.
Noteworthy progress has been made in this therapeutic class since the Exenatide
injection, produced by Amylin Pharmaceuticals, Inc. and Eli Lilly and Company, marketed
under the name Byetta®, which is a GLP-1 RA, received approval for treatment of T2D
Molecules 2022 ,27, 4315 4 of 10
in 2005. Nowadays, various GLP-1 RA drug products are clinically prescribed and used
in T2D. These medications also aid in weight loss, reduce the risk of hypoglycemia, and
contribute to cardiorenal protective effects along with providing good glycemic control [ 26].
For the treatment of T2D, Semaglutide (Ozempic), which is also a GLP-1 RA, is widely
used. The subcutaneous administration of Semaglutide as an add-on treatment along with
Metformin has been approved by the USFDA and EMEA. An oral form of Simaglutide to
be administered once a week is also available [27].
4. Tirzepatide
In early 2016, Eli Lilly and Company (Indianapolis, IN, USA) ﬁrst applied a method
of glycemic control using tirzepatide [ 28]. On 14 May 2022, Eli Lilly unlocked one more
achievement by receiving US FDA approval for the highly anticipated anti-diabetic drug
Mounjaro®(tirzepatide). Tirzepatide is a peptide molecule that is produced synthetically
that acts on both GIP and GLP-1 receptors as a receptor agonist. Due to this unique dual
activity property, it is also referred to as ‘twincretin’. Subcutaneous administration once a
week is adequate, as it possesses a half-life of about 5 days [29].
4.1. Structure and Activity
Tirzepatide is a synthetic linear peptide molecule containing 39 amino acids. Residues
derive from GLP-1, GIP and semaglutide, and a few residues are unique [ 30]. More
speciﬁcally, the structure is based on the native GIP sequence and includes C20 fatty
diacid moiety (eicosanedioic acid) linked via hydrophilic linkers ( -Glu-2xAdo, gamma
glutamate and bis-aminodiethoxyacetyl) connected to lysine residue at C20 position [ 31].
The peptide sequence of tirzepatide contains two non-coded amino acid residues (Aib,
-amino isobutyric acid) at position 2 and 13, which are responsible for its long half-life and
high afﬁnity to albumin [ 32]. The C-terminus of the peptide is amidated (Figure 2) [ 33]. The
molecular formula of tirzepatide is C 225H348N48O68and the molecular weight is 4813.45.
Tirzepatide is the ﬁrst agent that functions as a dual agonist for the two main human GLP-1
and GIP incretins, a promising drug against both T2D and obesity [ 34–37]. It has impressive
glycemic efﬁcacy. Moreover, it is the ﬁrst effective drug to have demonstrated notable body
weight loss in a phase 3 study in patients with T2D [38–40].
Molecules  2022, 27, x FOR PEER REVIEW   5 of 10 
 
 
 
Figure 2. Structural  features of tirzepatide,  amino acids are denoted as single‐letter codes. 
Tirzepatide  has significantly  better therapeutic  efficacy than current drugs [20,41]. It 
is superior to semaglutide  [33,42] and insulin degludec  [33,43]. The main critical improve‐
ments are modification  of residues in the peptide backbone  to obtain GIP receptor‐acti‐
vating activity, prolongation  of the C‐terminus  with a sequence  of C‐terminal of ex‐
enatide, and conjugation  of the fatty acid side chain to prolong half‐life (116.7 h) [30,44]. 
In addition,  hepatoprotection  cannot be overlooked  [45]. The structural  basis of tir‐
zepatide  in terms of its functional  versatility  has been reported  [46], and its physiological  
mechanisms  in T2D described  [47]. In the human clinical trial (NCT03951753),  tirzepatide  
was compared  to semaglutide  and placebo with respect to T2D patients’  responses  to 
blood sugar levels after a meal over 28 weeks. It was noted that tirzepatide  significantly  
improved  clamp disposition  index when compared  to both semaglutide  and placebo. This 
in turn showed significant  improvements  in total insulin secretion  rate and insulin sensi‐
tivity for tirzepatide.  Upon meal tolerance  testing, tirzepatide  was also noted to slow glu‐
cose excursions  when compared  with placebo. As such, tirzepatide  was found to be effi‐
cacious in treating T2D [47,48]. 
4.2. Synthesis  
Recently,  Micheal O. Frederick  and co‐workers from Eli Lilly and company  demon‐
strated a continuous  kilogram ‐scale GMP manufacturing  method for the synthesis  of tir‐
zepatide  using a hybrid solid‐phase peptide synthesis/liquid ‐phase peptide synthesis  
(SPPS/LPPS)  approach  [49]. This strategy also includes nanofiltration  for purifying  the 
intermediates,  and real‐time analytical  monitoring,  which resulted in the development  of 
robust synthetic  process with high purity and yield. Considering  both the pros and cons 
of SPPS and LPPS, the researchers  selected the four fragments  (Figure 3) that had the high‐
est purity and were readily isolable for the synthesis  of tirzepatide.  These four fragments  
were synthesized  through SPPS, and the coupling  of these fragments  was carried out us‐
ing LPPS. 
The LPPS portion of the synthesis  consisted  of four steps and was carried out in a 
plug‐flow reactor (PFR) [50]. In step 1, fragment  1 and 2 were coupled.  Separate  solutions  
of fragment  1 and 2 in dimethylsulfoxide  (DMSO)/acetonitrile  (ACN), [Ethyl cyano(hy ‐
droxyimino)acetato ‐O2]tri‐1‐pyrrolidinylphosphonium  hexafluorophosphate  (PyOxim)  
in ACN, and N,N′‐diisopropylethylamine  (DIPEA)  were made previously  and brought 
together in flow prior to entering the PFR. The PFR was coupled with an HPLC for reac‐
tion monitoring.  Once coupling  was performed,  the coupled fragment  was deprotected  
using diethylamine  (DEA). The deprotected  product was then purified using nanofiltra ‐
tion [51], a membrane ‐based technology,  where components  of the mixture could be sep‐
arated based on their molecular  weight and hydrophobicity.  Similarly,  fragment  3 was 
then coupled with the coupled product of fragments  1 and 2 in step 2, and so on for step 
3, in which fragment  4 was coupled.  In the final step, 19 acid‐labile protecting  groups were 
cleaved using trifluoroacetic  acid (TFA). Thus, 8.71 kg pure tirzepatide  was isolated, 
Figure 2. Structural features of tirzepatide, amino acids are denoted as single-letter codes.
Tirzepatide has signiﬁcantly better therapeutic efﬁcacy than current drugs [ 20,41]. It is
superior to semaglutide [ 33,42] and insulin degludec [ 33,43]. The main critical improve-
ments are modiﬁcation of residues in the peptide backbone to obtain GIP receptor-activating
activity, prolongation of the C-terminus with a sequence of C-terminal of exenatide, and
conjugation of the fatty acid side chain to prolong half-life (116.7 h) [ 30,44]. In addition,
hepatoprotection cannot be overlooked [ 45]. The structural basis of tirzepatide in terms
of its functional versatility has been reported [ 46], and its physiological mechanisms in
T2D described [ 47]. In the human clinical trial (NCT03951753), tirzepatide was com-
pared to semaglutide and placebo with respect to T2D patients’ responses to blood sugar
Molecules 2022 ,27, 4315 5 of 10
levels after a meal over 28 weeks. It was noted that tirzepatide signiﬁcantly improved
clamp disposition index when compared to both semaglutide and placebo. This in turn
showed signiﬁcant improvements in total insulin secretion rate and insulin sensitivity
for tirzepatide. Upon meal tolerance testing, tirzepatide was also noted to slow glucose
excursions when compared with placebo. As such, tirzepatide was found to be efﬁcacious
in treating T2D [47,48].
4.2. Synthesis
Recently, Micheal O. Frederick and co-workers from Eli Lilly and company demon-
strated a continuous kilogram-scale GMP manufacturing method for the synthesis of
tirzepatide using a hybrid solid-phase peptide synthesis/liquid-phase peptide synthesis
(SPPS/LPPS) approach [ 49]. This strategy also includes nanoﬁltration for purifying the
intermediates, and real-time analytical monitoring, which resulted in the development of
robust synthetic process with high purity and yield. Considering both the pros and cons of
SPPS and LPPS, the researchers selected the four fragments (Figure 3) that had the highest
purity and were readily isolable for the synthesis of tirzepatide. These four fragments
were synthesized through SPPS, and the coupling of these fragments was carried out using
LPPS.
Molecules  2022, 27, x FOR PEER REVIEW   6 of 10 
 
 representing  an overall yield of 81%. The described  hybrid approach  decreased  the man‐
ufacturing  risk and also created a robust continuous  manufacturing  method affording  
high purity and yield. 
 
Figure 3. Fragments  used to synthesize  tirzepatide  using the SPPS/LPPS  approach.  
4.3. Clinical Development  
Phase 1 clinical trials, which lasted for 4 weeks, followed  by 4 weeks of safety inves‐
tigation, for tirzepatide  showed a remarkable  statistical  decrease  in HbA1c, and postpran ‐
dial glucose levels were also found to be diminished.  A 26‐week‐long phase 2 clinical trial, 
which also included  a dulaglutide  group, showed better efficacy over dulaglutide.  It also 
contributed  to reduction  of weight and decreased  appetite in the subjects. In the SUR‐
PASS‐1 phase 3 clinical trials, which included  six countries  worldwide,  patients who had 
ongoing treatment  with SGLT2 inhibitors  (e.g., dapagliflozin)  were included.  Some trials 
included  consequent  administration  of tirzepatide  with dapagliflozin,  which resulted in 
higher HbA1c reduction  and weight loss [52]. In addition,  in the SURPASS ‐2 phase 3 clin‐
ical trial, which compared  tirzepatide  with metformin  to the selective  GLP‐1 receptor ag‐
onist semaglutide,  1 mg administered  once a week [53] showed additive effects. Some 
other additional  effects of tirzepatide  were noted to lowering  of the concentrations  of very 
low‐density lipoproteins  and triglycerides,  in addition to a reduction  in blood pressure,  
as well as an elevation  in high‐density lipoprotein  concentration.  The adverse events most 
commonly  reported  were nausea, vomiting,  and diarrhea,  which were mild to moderate  
and occurred  mostly during the dose‐escalation  period [40,54]. Further, in a phase 2 hu‐
man clinical study with tirzepatide  in conjunction  with regulated  nutrition  and lifestyle 
with or without metformin,  a dose‐dependent  impact on HbA1c and weight loss was ob‐
served, which was larger than that of the selective  GLP‐1 RA dulaglutide.  Meanwhile,  in 
a 12‐week phase 2 trial with moderate  dose‐escalation  regimens,  gastrointestinal  tolera‐
bility improved  when starting with a lower dose and slowly increasing  to the highest ef‐
fective doses [55–57]. Mechanism  of action of trizepatide  is presented  in Figure 4. 
Figure 3. Fragments used to synthesize tirzepatide using the SPPS/LPPS approach.
The LPPS portion of the synthesis consisted of four steps and was carried out in
a plug-ﬂow reactor (PFR) [ 50]. In step 1, fragment 1 and 2 were coupled. Separate so-
lutions of fragment 1 and 2 in dimethylsulfoxide (DMSO)/acetonitrile (ACN), [Ethyl
cyano(hydroxyimino)acetato- O2]tri-1-pyrrolidinylphosphonium hexaﬂuorophosphate (Py-
Oxim) in ACN, and N,N0-diisopropylethylamine (DIPEA) were made previously and
brought together in ﬂow prior to entering the PFR. The PFR was coupled with an HPLC
for reaction monitoring. Once coupling was performed, the coupled fragment was de-
protected using diethylamine (DEA). The deprotected product was then puriﬁed using
nanoﬁltration [ 51], a membrane-based technology, where components of the mixture could
be separated based on their molecular weight and hydrophobicity. Similarly, fragment
3 was then coupled with the coupled product of fragments 1 and 2 in step 2, and so on
for step 3, in which fragment 4 was coupled. In the ﬁnal step, 19 acid-labile protecting
groups were cleaved using triﬂuoroacetic acid (TFA). Thus, 8.71 kg pure tirzepatide was
Molecules 2022 ,27, 4315 6 of 10
isolated, representing an overall yield of 81%. The described hybrid approach decreased the
manufacturing risk and also created a robust continuous manufacturing method affording
high purity and yield.
4.3. Clinical Development
Phase 1 clinical trials, which lasted for 4 weeks, followed by 4 weeks of safety investi-
gation, for tirzepatide showed a remarkable statistical decrease in HbA1c, and postprandial
glucose levels were also found to be diminished. A 26-week-long phase 2 clinical trial,
which also included a dulaglutide group, showed better efﬁcacy over dulaglutide. It
also contributed to reduction of weight and decreased appetite in the subjects. In the
SURPASS-1 phase 3 clinical trials, which included six countries worldwide, patients who
had ongoing treatment with SGLT2 inhibitors (e.g., dapagliﬂozin) were included. Some
trials included consequent administration of tirzepatide with dapagliﬂozin, which resulted
in higher HbA1c reduction and weight loss [ 52]. In addition, in the SURPASS-2 phase 3
clinical trial, which compared tirzepatide with metformin to the selective GLP-1 receptor
agonist semaglutide, 1 mg administered once a week [ 53] showed additive effects. Some
other additional effects of tirzepatide were noted to lowering of the concentrations of very
low-density lipoproteins and triglycerides, in addition to a reduction in blood pressure, as
well as an elevation in high-density lipoprotein concentration. The adverse events most
commonly reported were nausea, vomiting, and diarrhea, which were mild to moderate
and occurred mostly during the dose-escalation period [ 40,54]. Further, in a phase 2 human
clinical study with tirzepatide in conjunction with regulated nutrition and lifestyle with or
without metformin, a dose-dependent impact on HbA1c and weight loss was observed,
which was larger than that of the selective GLP-1 RA dulaglutide. Meanwhile, in a 12-week
phase 2 trial with moderate dose-escalation regimens, gastrointestinal tolerability improved
when starting with a lower dose and slowly increasing to the highest effective doses [ 55–57].
Mechanism of action of trizepatide is presented in Figure 4.
Molecules  2022, 27, x FOR PEER REVIEW   7 of 10 
 
  
Figure 4. Mechanisms  of action of tirzepatide  within the human body. 
4.4. Pharmacokinetics  
In pharmacokinetic  (PK) studies in healthy volunteers  for doses ranging from 0.25 to 
15 mg peak plasma concentration  (Cmax), it was found to be dose proportional  ranging 
between 26 and 874 ng/mL. The maximal  concentration  (Tmax) for tirzepatide  was observed  
after 1–2 days of administration,  and the mean half‐life (T1/2) was found to be 116.7 h (i.e., 
5 days), thus favoring  a weekly dose regimen [58]. Steady‐state exposure  with a once‐a‐
week dose was found to be reached after 4 weeks, and the accumulation  index was found 
to be 1.6 during these 4 weeks. In patients with T2D, PK parameters  were studied for a 
final dose of 15 mg, and Cmax was noted to be 1250 ng/mL, while Tmax was found to be 24 h 
[53]. In addition,  further PK studies in healthy volunteers  over 28 days incorporated  a 
dose escalation  up to 10 mg, followed  by an oral glucose tolerance  test after 23 days of the 
initial dose, along with a placebo arm of dulaglutide  at a dose of 1.5 mg weekly. A signif‐
icantly improved  glucose response  was shown compared  with placebo for the glucose 
area under the curve (AUC  0‐2h) on the 23rd day following  the oral glucose tolerance  test. 
A reduction  in body weight of around −4.05 kg was found in the 10 mg dose subjects [26]. 
In summary,  peptide molecules  like semaglutide  and tirzepatide  have provided  
promising  results for reducing  HbA1c and reducing  body weight in human phase 1 and 
phase 2 clinical trials. The SURPASS ‐1 to SURPASS ‐5 human clinical trials provided  fa‐
vorable results in comparison  with similar moieties like semaglutide  and dulaglutide  
[59,60]. The US FDA approval  for tirzepatide  is believed to have provided  a step forward 
in the management  and treatment  of T2D and achieving  weight loss, acting as a one‐stop 
solution.  
5. Conclusions  
T2D and obesity are deep‐rooted diseases that have no specific cure so far, but can 
be kept under control by proper application  of therapy and treatment,  as well as incorpo‐
rating lifestyle modifications.  The alarming  increase in the number of patients worldwide  
requires new scientific  developments  in order to ease administration,  reduce the fre‐
quency of dosing, and address multiple  issues within a single medication.  Tirzepatide  has 
shown promising  results in terms of reducing  HbA1c and reducing  body weight in phase 
1 and phase 2 clinical trials. SURPASS ‐1 to SURPASS ‐5 human clinical trials have given 
favorable  results by comparison  with similar moieties such as, semaglutide  and dulag‐
lutide. The USFDA has approved  tirzepatide  under the brand name Mounjaro,  which has 
become a revolutionary  agent for the management  and treatment  of T2D and achieving  
weight loss [29,61,62].  Patient compliance  and dose adherence  are also favored, since it 
has the advantage  of a once‐a‐week dose administration.  
Figure 4. Mechanisms of action of tirzepatide within the human body.
4.4. Pharmacokinetics
In pharmacokinetic (PK) studies in healthy volunteers for doses ranging from 0.25
to 15 mg peak plasma concentration (C max), it was found to be dose proportional ranging
between 26 and 874 ng/mL. The maximal concentration (T max) for tirzepatide was observed
after 1–2 days of administration, and the mean half-life (T 1/2) was found to be 116.7 h
(i.e., 5 days), thus favoring a weekly dose regimen [ 58]. Steady-state exposure with a
once-a-week dose was found to be reached after 4 weeks, and the accumulation index was
found to be 1.6 during these 4 weeks. In patients with T2D, PK parameters were studied for
a ﬁnal dose of 15 mg, and C maxwas noted to be 1250 ng/mL, while T maxwas found to be
24 h [ 53]. In addition, further PK studies in healthy volunteers over 28 days incorporated
Molecules 2022 ,27, 4315 7 of 10
a dose escalation up to 10 mg, followed by an oral glucose tolerance test after 23 days of
the initial dose, along with a placebo arm of dulaglutide at a dose of 1.5 mg weekly. A
signiﬁcantly improved glucose response was shown compared with placebo for the glucose
area under the curve (AUC 0-2h) on the 23rd day following the oral glucose tolerance test.
A reduction in body weight of around  4.05 kg was found in the 10 mg dose subjects [ 26].
In summary, peptide molecules like semaglutide and tirzepatide have provided
promising results for reducing HbA1c and reducing body weight in human phase 1 and
phase 2 clinical trials. The SURPASS-1 to SURPASS-5 human clinical trials provided favor-
able results in comparison with similar moieties like semaglutide and dulaglutide [ 59,60].
The US FDA approval for tirzepatide is believed to have provided a step forward in the
management and treatment of T2D and achieving weight loss, acting as a one-stop solution.
5. Conclusions
T2D and obesity are deep-rooted diseases that have no speciﬁc cure so far, but can be
kept under control by proper application of therapy and treatment, as well as incorporating
lifestyle modiﬁcations. The alarming increase in the number of patients worldwide requires
new scientiﬁc developments in order to ease administration, reduce the frequency of dosing,
and address multiple issues within a single medication. Tirzepatide has shown promising
results in terms of reducing HbA1c and reducing body weight in phase 1 and phase 2
clinical trials. SURPASS-1 to SURPASS-5 human clinical trials have given favorable results
by comparison with similar moieties such as, semaglutide and dulaglutide. The USFDA has
approved tirzepatide under the brand name Mounjaro, which has become a revolutionary
agent for the management and treatment of T2D and achieving weight loss [ 29,61,62].
Patient compliance and dose adherence are also favored, since it has the advantage of a
once-a-week dose administration.
Thus, tirzepatide could be a breakthrough in the treatment of T2D. As such, further
research in synthetic peptide therapeutics will gain increasing momentum from now on.
Author Contributions: V .P .C. created the plot of the manuscript and drafted the ﬁrst draft with the
help of J.A., D.T., J.B. and V .A.; V .P .C., J.B. and V .A. critically revised the manuscript. All authors have
read and agreed to the published version of the manuscript.
Funding: This research received no external funding.
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: Not applicable.
Acknowledgments: V .P .C. wants to dedicate this manuscript to the 75th year celebration of L M
College of Pharmacy, Ahmedabad, India. The ﬁgures were created with Biorender.com (accessed on 1
June 2021).
Conﬂicts of Interest: The authors declare no conﬂict of interest.
Sample Availability: Samples of the compounds are not available from the authors.
References
1. Sheldon, T.A.; Wright, J. Twin epidemics of COVID-19 and non-communicable disease. BMJ 2020 ,369, 2618. [CrossRef] [PubMed]
2. Kumar, M.; Sarma, D.K.; Shubham, S.; Kumawat, M.; Verma, V .; Prakash, A.; Tiwari, R. Environmental endocrine-disrupting
chemical exposure: Role in non-communicable diseases. Front. Public Health 2020 ,8, 553850. [CrossRef] [PubMed]
3. Mancilla, V .J.; Peeri, N.C.; Silzer, T.; Basha, R.; Felini, M.; Jones, H.P .; Phillips, N.; Tao, M.H.; Thyagarajan, S.; Vishwanatha, J.K.
Understanding the interplay between health disparities and epigenomics. Front. Genet. 2020 ,11, 903. [CrossRef] [PubMed]
4. Abdelaal, M.; le Roux, C.W.; Docherty, N.G. Morbidity and mortality associated with obesity. Ann. Transl. Med. 2017 ,5, 161–173.
[CrossRef]
5. World Health Organization. Obesity and Overweight. 2021. Available online: https://www.who.int/news-room/fact-sheets/
detail/obesity-and-overweight (accessed on 5 May 2022).
6. World Health Organization. Obesity: Preventing and Managing the Global Epidemic ; Technical Report; WHO: Geneva, Switzerland,
2000.
Molecules 2022 ,27, 4315 8 of 10
7. Guh, P .; Zhang, W.; Bansback, N.; Amarsi, Z.; Birmingham, C.L.; Anis, A.H. The incidence of co-morbidities related to obesity
and overweight: A systematic review and meta-analysis. BMC Public Health 2009 ,9, 88–120. [CrossRef]
8. World Health Organization (WHO). Diabetes, Key Facts ; WHO: Geneva, Switzerland, 10 November 2021. Available online:
https://www.who.int/news-room/fact-sheets/detail/diabetes (accessed on 5 May 2022).
9. Alam, S.; Hasan, M.K.; Neaz, S.; Hussain, N.; Hossain, M.F.; Rahman, T. Diabetes mellitus: Insights from epidemiology,
biochemistry, risk factors, diagnosis, complications and comprehensive management. Diabetology 2021 ,2, 36–50. [CrossRef]
10. Sun, H.; Saeedi, P .; Karuranga, S.; Karuranga, S.; Pinkepank, M.; Ogurtsova, K.; Duncan, B.B.; Stein, S.; Basit, A.; Chan, J.C.N.;
et al. IDF Diabetes atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.
Diabetes Res. Clin. Pract. 2022 ,183, 109119–109132. [CrossRef]
11. Lim, S.; Bae, J.H.; Kwon, H.S.; Nauck, M.A. COVID-19 and diabetes mellitus: From pathophysiology to clinical management. Nat.
Rev. Endocrinol. 2021 ,17, 11–30. [CrossRef]
12. Sebire, S.J.; Toumpakari, Z.; Turner, K.M.; Cooper, A.R.; Page, A.S.; Malpass, A.; Andrews, A.R. “ I’ve made this my lifestyle now ”: A
prospective qualitative study of motivation for lifestyle change among people with newly diagnosed type two diabetes mellitus.
BMC Public Health 2018 ,18, 204. [CrossRef]
13. Ganesan, K.; Rana, M.B.M.; Sultan, S. Oral Hypoglycemic Medications ; Updated 8 May 2022; StatPearls Publishing: Treasure Island,
FL, USA, 2022.
14. Costello, R.A.; Shivkumar, N.S. Sulfonylureas ; Updated 23 February 2022; StatPearls Publishing: Treasure Island, FL, USA, 2022.
15. Zeynaloo, E.; Stone, L.D.; Dikici, E.; Ricordi, C.; Deo, S.K.; Bachas, L.G.; Daunert, S.; Lanzoni, G. Delivery of therapeutic agents
and cells to pancreatic islets: Towards a new era in the treatment of diabetes. Mol. Aspects Med. 2022 ,83, 101063–101084.
[CrossRef]
16. Marín-Peñalver, J.J.; Mart ín-Tim ón, I.; Sevillano-Collantes, C.; Del Cañizo-G ómez, F.J. Update on the treatment of type 2 diabetes
mellitus. World J. Diabetes 2016 ,7, 354–395. [CrossRef] [PubMed]
17. Al-Tabakha, M.M. Future prospect of insulin inhalation for diabetic patients: The case of Afrezza versus Exubera. J. Control
Release 2015 ,215, 25–38. [CrossRef] [PubMed]
18. Modi, P . Diabetes beyond insulin: Review of new drugs for treatment of diabetes mellitus. Curr. Drug Discov. Technol. 2007 ,4,
39–47. [CrossRef] [PubMed]
19. Tupas, G.D.; Otero, M.C.B.; Ebhohimen, I.E.; Egbuna, C.; Aslam, M. Chapter 8—Antidiabetic Lead Compounds and Targets for
Drug Development. In Phytochemicals as Lead Compounds for New Drug Discovery ; Egbuna, C., Kumar, S., Ifemeje, J.C., Ezzat, S.M.,
Kaliyaperumal, S., Eds.; Elsevier: Amsterdam, The Netherlands, 2020; pp. 127–141.
20. Frias, J.P .; Nauck, M.A.; Van, J.; Kutner, M.E.; Cui, X.; Benson, C.; Urva, S.; Gimeno, R.E.; Milicevic, Z.; Robins, D.; et al.
Efﬁcacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: A randomised,
placebo-controlled and active comparator-controlled phase 2 trial. Lancet 2018 ,392, 2180–2193. [CrossRef]
21. Frias, J.P .; Nauck, M.A.; Van, J.; Benson, C.; Bray, R.; Cui, X.; Milicevic, Z.; Urva, S.; Haupt, A.; Robins, D.A. Efﬁcacy and tolerability
of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with
type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens.
Diabetes Obes. Metab. 2020 ,22, 938–946.
22. Apostolopoulos, V .; Bojarska, J.; Chai, T.-T.; Elnagdy, S.; Kaczmarek, K.; Matsoukas, J.; New, R.; Parang, K.; Lopez, O.P .; Parhiz, H.;
et al. A Global review on short peptides: Frontiers and perspectives. Molecules 2021 ,26, 430. [CrossRef]
23. Nauck, M.A.; Meier, J.J. The incretin effect in healthy individuals and those with type 2 diabetes: Physiology, pathophysiology,
and response to therapeutic interventions. Lancet Diabetes Endocrinol. 2016 ,4, 525–536. [CrossRef]
24. Müller, T.D.; Finan, B.; Bloom, S.R.; D’Alessio, D.; Drucker, D.J.; Flatt, P .R.; Fritsche, A.; Gribble, F.; Grill, H.J.; Habaner, J.F.; et al.
Glucagon-like peptide 1 (GLP-1). Mol. Metab. 2019 ,30, 72–130. [CrossRef]
25. Gupta, S.; Sen, U. More than just an enzyme: Dipeptidyl peptidase-4 (DPP-4) and its association with diabetic kidney remodelling.
Pharmacol. Res. 2019 ,147, 104391–104403. [CrossRef]
26. Frías, J.P . Tirzepatide: A glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist
in development for the treatment of type 2 diabetes. Expert Rev. Endocrinol. Metab. 2020 ,15, 379–394. [CrossRef]
27. Andreadis, P .; Karagiannis, T.; Malandris, K.; Avgerinos, I.; Liakos, A.; Manolopoulos, A.; Beklari, E.; Matthews, D.R.; Tsapas,
A. Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Obes. Metab. 2018 ,20, 2255–2263.
[CrossRef]
28. Bokvist, B.K.; Coskun, T.; Cummins, R.C.; Alsina-Fernandez, J. GIP and GLP-1 Co-Agonist Compounds. U.S. Patent 947478, 25
October 2016.
29. Jastreboff, A.M.; Aronne, L.J.; Ahmad, N.N.; Wharton, S.; Connery, L.; Alves, B.; Kiyosue, A.; Zhang, S.; Liu, B.; Bunck, M.C.; et al.
Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 2022 ,11, 127. [CrossRef]
30. Wang, L. Designing a dual GLP-I R/GIPR agonist from tirzepatide: Comparing residues between tirzepatide, GLP-I, and GIP .
Drug Des. Dev. Ther. 2022 ,16, 1547–1560. [CrossRef] [PubMed]
31. Cosku, T.; Sloop, K.W.; Loghin, C.; Alsina-Fernandez, J.; Urva, S.; Bokvist, K.B.; Cui, X.; Briere, D.A.; Cabrera, O.; Roell, W.C.; et al.
LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical
proof of concept. Mol. Metab. 2018 ,18, 3–14. [CrossRef]
Molecules 2022 ,27, 4315 9 of 10
32. Østergaard, S.; Paulsson, J.F.; Kofoed, J.; Zosel, F.; Olsen, J.; Jeppesen, C.B.; Spetzler, J.; Ynddal, L.; Schleiss, L.G.; Christoffersen,
B.Ø.; et al. The effect of fatty diacid acylation of human PYY3-36 on Y2 receptor potency and half-life in minipigs. Sci. Rep. 2021 ,
11, 21179–21194. [CrossRef] [PubMed]
33. Sun, B.; Willard, F.S.; Feng, D.; Alsina-Fernandez, J.; Chen, Q.; Vieth, M.; Ho, J.D.; Showalter, A.D.; Stutsman, C.; Ding,
L.; et al. Structural determinants of dual incretin receptor agonism by tirzepatide. Proc. Natl. Acad. Sci. USA 2022 ,119,
211650611–211650622. [CrossRef] [PubMed]
34. Chow, E.; Chan, J.C.N. The emerging role of incretins and twincretins. Nat. Rev. Endocrinol. 2021 ,18, 73–74. [CrossRef]
35. Fisman, E.Z.; Tenenbaum, A. The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1)
receptor agonist tirzepatide: A novel cardiometabolic therapeutic prospect. Cardiovasc. Diabetol. 2022 ,20, 225–230. [CrossRef]
36. Nowak, M.; Nowak, W.; Grzeszczak, W. Tirzepatide-a dual GIP/GLP-1 receptor agonist—A new antidiabetic drug with potential
metabolic activity in the treatment of type 2 diabetes. Endokrynol. Pol. 2022 , 1–11. [CrossRef]
37. Starling, S. GIP-GLP1 receptor agonist shows promise. Nat. Rev. Endocrinol. 2022 ,18, 391. [CrossRef]
38. Dutta, D.; Surana, V .; Singla, R.; Aggarwal, S.; Sharma, M. Efﬁcacy and safety of novel twincretin tirzepatide a dual GIP and
GLP-1 receptor agonist in the management of type-2 diabetes: A cochrane meta-analysis. Indian J. Endocrinol. Metab. 2021 ,25,
475–490. [CrossRef] [PubMed]
39. Pelle, M.C.; Provenzano, M.; Zafﬁna, I.; Pujia, R.; Giofr è, F.; Luc à, S.; Andreucci, M.; Sciacqua, A.; Arturi, F. Role of a dual
glucose-dependent insulinotropic peptide (GIP)/glucagon-like peptide-1 receptor agonist (twincretin) in glycemic control: From
pathophysiology to treatment. Life2022 ,12, 29. [CrossRef] [PubMed]
40. Karagiannis, T.; Avgerinos, I.; Liakos, A.; Del Prato, S.; Matthews, D.R.; Tsapas, A.; Bekiari, E. Management of type 2 diabetes
with the dual GIP/GLP-1 receptor agonist tirzepatide: A systematic review and meta-analysis. Diabetologia 2022 , 1–11. [CrossRef]
41. Willard, F.S.; Douros, J.D.; Gabe, M.B.; Showalter, A.D.; Wainscott, D.B.; Suter, T.M.; Capozzi, M.E.; van der Welden, W.J.C.;
Stutsman, C.; Cardona, G.R.; et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight 2020 ,
5, e140532–e140549. [CrossRef]
42. Scheen, A.J. Add-on value of trizepatide versus semaglutide. Lancet Diabetes Endocrinol. 2022 ,10, 377–378. [CrossRef]
43. Gastaldelli, A.; Cusi, K.; Lando, L.F.; Bray, R.; Brouwers, B.; Rodriguez, A. Effect of trizepatide versus insulin degludec on liver
fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): A substudy of the randomised,
open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022 ,10, 393–406. [CrossRef]
44. Ahangarpour, M.; Kavianinia, I.; Harris, P .W.; Brimble, M.A. Photo-induced radical thiol-ene chemistry: A versatile toolbox for
peptide-based drug design. Chem. Soc. Rev. 2021 ,50, 898–944. [CrossRef]
45. Targher, G. Tirzepatide adds hepatoprotection to its armoury. Lancet Diabetes Endocrinol. 2022 ,10, 374–375. [CrossRef]
46. Zhao, F.; Zhou, Q.; Cong, Z.; Hang, K.; Zou, X.; Zhang, C.; Chen, Y.; Dai, A.; Liang, A.; Ming, Q.; et al. Structural insight into
multiplexed pharmacological actions of trizepatide and peptide 20 at the GIP , GLP-1 or glucagon receptors. Nat. Commun. 2022 ,
13, 1057–1073. [CrossRef]
47. Heise, T.; Mari, A.; DeVries, J.H.; Urva, S.; Li, J.; Pratt, E.J.; Coskun, T.; Thomas, M.K.; Mather, K.J.; Haupt, A.; et al. Effects of
subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type
2 diabetes: A multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial. Lancet Diabetes Endocrinol. 2022 ,10,
418–429. [CrossRef]
48. Chipkin, S.R. Tirzepatide for patients with type 2 diabetes. JAMA 2022 ,327, 529–530. [CrossRef] [PubMed]
49. Frederick, M.O.; Boyse, R.A.; Braden, T.M.; Calvin, J.R.; Campbell, B.M.; Changi, S.M.; Cofﬁn, S.R.; Condon, C.; Gowran,
O.; McClary, J.; et al. Kilogram-scale GMP manufacture of tirzepatide using a hybrid SPPS/LPPS approach with continuous
manufacturing. Org. Process Res. Dev. 2021 ,25, 1628–1636. [CrossRef]
50. May, S.A.; Johnson, M.D.; Buser, J.Y.; Campbell, A.N.; Frank, S.A.; Haeberle, B.D.; Hoffman, P .C.; Lambertus, G.R.; McFarland,
A.D.; Moher, E.D.; et al. Development and manufacturing GMP scale-up of a continuous ir-catalyzed homogeneous reductive
amination reaction. Org. Process Res. Dev. 2016 ,20, 1870–1898. [CrossRef]
51. Wang, Z.; Wang, Z.; Lin, S.; Jin, H.; Gao, S.; Zhu, Y.; Jin, J. Nanoparticle-templated nanoﬁltration membranes for ultrahigh
performance desalination. Nat. Commun. 2018 ,9, 2004–2013. [CrossRef] [PubMed]
52. Min, T.; Bain, S.C. The role of tirzepatide, dual GIP and GLP-1 receptor agonist, in the management of type 2 diabetes: The
SURPASS clinical trials. Diabetes Ther. 2021 ,12, 143–157. [CrossRef]
53. Ludvik, B.; Giorgino, F.; J ódar, E.; Frias, J.P .; Land ó, L.F.; Brown, K.; Bray, R.; Rodr íguez, A. Once-weekly tirzepatide versus once-
daily insulin degludec as add-on to metformin with or without SGLT2 inhibitors in patients with type 2 diabetes (SURPASS-3): A
randomised, open-label, parallel-group, phase 3 trial. Lancet 2021 ,398, 583–598. [CrossRef]
54. Frías, J.P .; Davies, M.J.; Rosenstock, J.; P érez Manghi, F.C.; Fern ández Land ó, L.; Bergman, B.K.; Liu, B.; Cui, X.; Brown, K.
Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N. Engl. J. Med. 2021 ,385, 503–515. [CrossRef]
55. Apostolopoulos, V .; Bojarska, J.; Chai, T.-T.; Feehan, J.; Kaczmarek, K.; Matsoukas, J.M.; Paredes Lopez, O.; Saviano, M.;
Skwarczynski, M.; Smith-Carpenter, J.; et al. New advances in short peptides: Looking forward. Molecules 2022 ,27, 3635.
[CrossRef]
56. Apostolopoulos, V .; Bojarska, J.; Feehan, J.; Matsoukas, J.; Wolf, W. Smart therapies for pandemics: A potential of short peptides.
Front. Pharmacol. 2022; accepted . [CrossRef]
Molecules 2022 ,27, 4315 10 of 10
57. Ohwaki, K.; Furihata, K.; Mimura, M.; Oura, T.; Imaoka, T. 1024-P: Effect of tirzepatide, a dual GIP and GLP-1 receptor agonist,
on glycemic control and body weight in Japanese patients with T2DM. Diabetes 2019 ,68(Suppl. S1). [CrossRef]
58. Furihata, K.; Mimura, H.; Urva, S.; Oura, T.; Ohwaki, K.; Imaoka, T. A phase 1 multiple-ascending dose study of tirzepatide in
Japanese participants with type 2 diabetes. Diabetes Obes. Metab. 2022 ,24, 239–246. [CrossRef]
59. Thomas, M.K.; Nikooienejad, A.; Bray, R.; Cui, X.; Wilson, J.; Dufﬁn, K.; Milicevic, Z.; Haupt, A.; A Robins, D. Dual GIP and
GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity in type 2 diabetes. J. Clin. Endocrinol. Metab.
2021 ,106, 388–396. [CrossRef] [PubMed]
60. Dahl, D.; Onishi, Y.; Norwood, P .; Huh, R.; Bray, R.; Patel, H.; Rodr íguez, Á. Effect of subcutaneous tirzepatide vs. placebo added
to titrated insulin glargine on glycemic control in patients with type 2 diabetes: The SURPASS-5 randomized clinical trial. JAMA
2022 ,327, 534–545. [CrossRef] [PubMed]
61. Mullard, A. Lilly’s tirzepatide secures ﬁrst approval in diabetes, paving path for dual-acting hormone mimetics. Nat. Rev. Drug
Discov. 2022 ,21, 480. [CrossRef] [PubMed]
62. Moura, F.A.; Scirica, B.M.; Ruff, C.T. Tirzepatide for diabetes: On track to SURPASS current therapy. Nat. Med. 2022 ,28, 450–451.
[CrossRef] [PubMed]